Clinical Trials · NCT01780220
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- UNICANCER
- Enrollment
- 47
- Start date
- Dec 2012
- Locations
- 5 sites, France
- Primary endpoint
- to determine the maximum tolerated dose and the phase II recommended dose of abiraterone acetate treatment plus prednisone and LH-RH agonist combined with prostate radiotherapy